Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the pharmacokinetic and pharmacodynamic parameters of
rivaroxaban and apixaban in patients with compensated liver cirrhosis (Child-Pugh class A and
B).
The enrolled participants receive a prophylactic single oral dose of either rivaroxaban (10
mg) or apixaban (2.5 mg) at around 8 a.m. on the day of the trial. Blood samples are taken
0.5 hours pre-dose and 1, 2, 3, 4, 6, 8, 12 hours post-dose.
A follow-up telephone call is performed 5 days after the study intervention to collect safety
data.